CDG Capital
晨岭资本
CDG Capital (晨岭资本) is a Chinese investment fund active in the healthcare and biotech space, appearing as a recurring participant in growth-stage financing rounds during 2021. Per 峰瑞资本 (FreeS Capital) and 高榕创投 (Gaorong Ventures) reporting from that year, it co-invested in Singleron Biotechnologies' nearly $100 million Series B alongside lead investor Lake Bleu Capital and fellow backers Lilly Asia Ventures, ARCH Venture Partners, and others . It also joined Mirxes' $87 million Series C round for miRNA-based early cancer screening, alongside investors including China Resources Capital, Rock Springs Capital, and EDBI . elsewhere's corpus does not contain information on its founding, AUM, or more recent activity.
AI-generated — may contain errors, please verify.
Coverage
3 Biopharma Companies Raise Over 1 Billion Yuan Combined | FreeS Family Funding News · October–November
Firmly bullish on the development of biomedical innovation in China
Gaorong Monthly · October | Gaorong Ventures Named Among Zero2IPO's Top 10 VC Firms of the Year; Nuro Closes Major Series D Round
Autonomous driving, healthcare, and chip sectors see new funding rounds; Genki Forest unveils "Triple Zero Factory" strategy; Dingdong Maicai stabilizes prices and ensures supply.
Mirxes Completes $87 Million Series C Round to Develop Early Cancer Screening Products Based on Leading miRNA Technology
Focused on microRNA technology, dedicated to early disease diagnosis.
